Register Here

2019 Executive Sponsors

Adaptive Biotechnologies
Cofactor Genomics
Imaging Endpoints
Mitra Biotech
NeoGenomics
Q² Solutions

2019 Associate Sponsors

Cello Health BioConsulting
ERT
Mint Medical
nanoString Technologies
Neon Therapeutics

2019 Showcase Sponsors

BioXcel Therapeutics
Provecs Medical

2019 Exhibitors

Caprion

2019 Supporting Sponsors

Exicure

2019 Supporting & Educational Partners

Alliance for Regenerative Medicine
CIMT
Cancer Research Institute CRI
Center for Biotechnology
Journal of Immunotherapy and Precision Oncology (JIPO)
SITC
Solebury Trout

2019 Media Partners

Pharmalicensing
PharmaVOICE
STAT news

Overview

IO360˚ convenes stakeholders spanning the science and business communities to report on data-driven advancements in immuno-oncology to fight a wider range of cancers.


Immuno-Oncology 360° delivers three key benefits:

  1. Access to KOLs driving the science
  2. Partnership opportunities with all stakeholders in Immuno-Oncology
  3. Presentations on the latest data affecting the science, clinical and business advancements in Immuno-Oncology

Immuno-Oncology 360° provides 10 plenary sessions over the course of 3 days addressing:

  • Discovery / Preclinical Science

  • Translational Science & Biomarkers

  • Clinical Data Developments

  • Clinical Operations

  • Imaging Aspects

  • Cell Therapy

  • Emerging Technologies

  • Business Aspects

  • Financial & Commercial Implications

  • Trends in the Field


2019 Featured Speakers

We would like to welcome Dr Andrew Baum, Citi as part of the 2019 lead advisory committee. Guided by Dr Andrew Baum, along with Dr Axel Hoos, GSK and Dr James Gulley, NCI, the 5th annual Immuno-Oncology 360° program includes more than 80 speakers and over 60 talks.



Immuno-Oncology 360° reports on the most current data and rapid advancements to help IO stakeholders:

  • Be at the forefront of the most relevant research and developments from key leadership who are at the pulse of cancer immunotherapy
  • Foster collaboration amongst those working in all aspects of cancer immunotherapy together under one roof
  • Partner to expand technology platforms to develop therapeutics at an accelerated rate
  • Receive the latest pre-clinical, translational and clinical data from academic and industry
  • Identify and gain a greater understanding of what assets are available for potential combinations
  • Create and prioritize strategies targeted toward specific tumor types
  • Hear from IO clinical trial leaders as they cover trial design, clinical operations, the latest outcomes and lessons learned
  • Get key investor and analyst evaluations and insights on the IO landscape, challenges and what’s next
  • Hear reports on industry trends from Endpoint News, BioCentury Innovations and Bloomberg Intelligence 
  • Learn about biomarker advancements in vaccines, imaging, neoantigen approaches and more
  • Obtain coverage on a wide range of emerging technologies

Dr David Lebwohl, Novartis discussed Learnings from Kymriah, the 1st CAR-T therapy approved by the FDA, from pivotal trials through commercialization.

Dr Andrew Baum, Citi addressed the Future Value Generation in IO at the 2018 IO360° program.

Dr Andy Lee and his entire Merck operations team walked the audience through the Building Blocks of IO trials in a new plenary session for the 2018 IO360° program.

 

If you are interested in participating in the 5th Annual Immuno-Oncology 360° 2019 program, please contact us at service@tcfllc.org. Thank you.

Sincerely,​

 

 

 

kate-bw-3

Kate Woda
Conference Director

Valerie Bowling New

Valerie Bowling
Executive Director

Meredith Sands
Executive Director, Business Development

geeta-new-bw

Geeta Bachani
Business Development Manager

elizabeth-bard-bw-2

Elizabeth Bard
Business Development Manager

Meg

Meg Gould
Conference Planner

Terri Sobol
Business Development Manager

Bre BugBee
Marketing Associate Manager


Testimonials

  • "By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there’s quite a lot of folks participating who are not traditionally talking to one another on a daily basis."

    - Roy Baynes, MD, PhD, Merck

  • "I really enjoyed it and connecting with some really interesting and inspiring people with whom I'm sure this is just the beginning of long standing interactions."

    - Jacqueline Karmel, Roche

  • "Thank you again for the amazing invitation, it was truly my pleasure to be able to participate in the excellent event you organized."

    - Christine Ward, BMS

  • "IO360° was one of the best immuno-oncology meetings I’ve been to. Kudos! Great speakers and great dialogue!"

    - Jim Mansfield, PerkinElmer

  • "Congratulations again on the excellent program for the Immuno-Oncology 360° meeting. It was truly well coordinated and the topics were fantastic!"

    - Gilson Baia, PhD, Champions Oncology

  • "Really good, well-rounded and novel content. Congratulations on filling the house beyond capacity and for securing such an impressive speaking faculty."

    - Eileen Daniels, Nektar Therapeutics

  • "Thank you for a great conference!"

    - Elena Spanjaard, Pfizer

  • "Your team did a wonderful job in putting together an interesting and relevant program."

    - Lew Bender, Intensity Therapeutics

  • "It was a great conference and I was happy to be a part of it."

    - Anna Pavlick, DO, MD, NYU Cancer Center